The discovery of several altered signaling pathways associated with ccRCC has opened new opportunities and strategies in the treatment of ccRCC, especially the targeted inhibition of molecules involved in VEGF and mTOR pathways (11–12). The gene discussed is VEGFA; the disease is nonpapillary renal cell carcinoma.